Oura smart ring IPO roadshow launches, targets $2.2 billion
Oura Health launched its IPO, aiming to raise $2.2B by selling 50M shares at $40-$44 each, targeting a $15.62B valuation. Trading under 'OURA' on Nasdaq, it sold 3.6M rings in the past year with $1.21B revenue. Eli Lilly and Dragoneer may invest $100M and $300M respectively. The company faces a lawsuit over sleep tracking accuracy claims.
How this was made
The 30-second read
Why it matters
The IPO provides a fresh entry point for investors and may set a pricing benchmark for wearable tech firms.
Market read
A sizable IPO in the consumer health sector amid a cautious market environment.
What to watch
Potential dilution from underwriter option and existing shareholder sell‑down could pressure price.
Background
Oura, a Finnish‑origin health‑tracking ring maker, moved headquarters to San Francisco and seeks a $15.6 billion valuation.
Ticker impact
Oura announced its IPO filing on Nasdaq, targeting up to $2.2 billion by selling 50 million shares.
Initial pricing pressure likely modest; post‑IPO volatility expected.
Primary disclosure of a multi‑billion IPO for a mid‑cap company; scale and novelty drive relevance.
Market effects
Highlights growing interest in consumer health wearables and may boost peer valuations.
Adds a new tech listing to the Nasdaq, modest effect on US markets.
Signals continued appetite for IPOs despite broader market fragility.
Counterpoint
Investors may be wary of the pending class‑action lawsuit and high valuation.
Key entities
- underwriterGoldman Sachs
Lead underwriter for Oura's IPO.
- potential investorEli Lilly
Indicated interest to buy up to $100 million of Oura shares.
